Protein kinase C epsilon regulation of translocator protein (18 kDa) Tspo gene expression is mediated through a MAPK pathway targeting STAT3 and c-Jun transcription factors.
Translocator protein TSPO is an 18 kDa protein implicated in numerous cell functions and is highly expressed in secretory and glandular tissues, especially in steroidogenic cells. TSPO expression is altered in pathological conditions such as certain cancers and neurological diseases. In search of the factors regulating Tspo expression, we recently showed that high levels of TSPO in steroidogenic cells may be due to high constitutive expression of protein kinase Cepsilon (PKCepsilon), while phorbol 12-myristate 13-acetate (PMA) activation of PKCepsilon drives inducible TSPO expression in nonsteroidogenic cells, likely through activator protein 1 (AP1). In this study, we aimed to identify the signal transduction pathway through which PKCepsilon regulates Tspo gene expression. The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts). AP1 and signal transducer and activation of transcription 3 (STAT3) have binding sites in the Tspo promoter and are downstream targets of PKCepsilon and MAPK (Raf-1-ERK1/2) pathways. PKCepsilon overexpression induced STAT3 phosphorylation in NIH-3T3 cells, while PKCepsilon knockdown reduced STAT3 and c-Jun phosphorylation in Leydig cells. MEK1/2, ERK2, c-Jun, and STAT3 knockdown reduced Tspo mRNA and protein levels in Leydig cells. Additionally, Raf-1 reduced Tspo mRNA levels in the same cells. MEK1/2, c-Jun, and STAT3 knockdown also reduced basal as well as PMA-induced Tspo mRNA levels in NIH-3T3 cells. Together, these results demonstrate that PKCepsilon regulates Tspo gene expression through a MAPK (Raf-1-MEK1/2-ERK1/2) signal transduction pathway, acting at least in part through c-Jun and STAT3 transcription factors.
Batarseh
Amani
A
Department of Biochemistry and Molecular and Cell Biology, Georgetown University Medical Center, Washington, DC 20057, USA.
Li
Jiehan
J
Papadopoulos
Vassilios
V
D000818:Animals; D019556:COS Cells; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D015971:Gene Expression Regulation, Enzymologic; D018390:Gene Targeting / Q000379:methods; D048369:MAP Kinase Kinase 1 / Q000502:physiology; D048370:MAP Kinase Kinase 2 / Q000502:physiology; D020935:MAP Kinase Signaling System / Q000235:genetics*; D051379:Mice; D041681:NIH 3T3 Cells; D011401:Promoter Regions, Genetic / Q000235:genetics; D051744:Protein Kinase C-epsilon / Q000502:physiology*; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism* / Q000502:physiology; D019908:Proto-Oncogene Proteins c-raf / Q000502:physiology; D018079:Receptors, GABA / Q000096:biosynthesis* / Q000172:deficiency / Q000235:genetics*; D050796:STAT3 Transcription Factor / Q000172:deficiency / Q000235:genetics / Q000378:metabolism* / Q000502:physiology
C463819:Bzrp protein, mouse; D016755:Proto-Oncogene Proteins c-jun; D018079:Receptors, GABA; D050796:STAT3 Transcription Factor; C494087:Stat3 protein, mouse; D019908:Proto-Oncogene Proteins c-raf; D051744:Protein Kinase C-epsilon; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; C482127:Map2k1 protein, mouse; C482129:Map2k2 protein, mouse
Antioxid Redox Signal. 2003 Oct;5(5):635-9
14580320
Clin Sci (Lond). 1990 Feb;78(2):155-8
2155741
Stem Cells. 1999;17(3):138-46
10342556
Endocrinology. 2002 Jul;143(7):2571-83
12072389
Biochemistry. 2008 Dec 2;47(48):12886-99
18975922
J Cell Biochem. 2006 Aug 15;98(6):1667-80
16637058
Clin Cancer Res. 2004 Mar 15;10(6):2058-64
15041726
Mol Cell Biol. 1999 Oct;19(10):7138-46
10490649
Endocrinology. 2004 Mar;145(3):1113-23
14630713
Biochem Pharmacol. 2003 Mar 1;65(5):717-29
12628485
Prog Growth Factor Res. 1989;1(2):69-77
2518808
Curr Pharm Des. 2007;13(23):2385-405
17692008
Nat Rev Cancer. 2007 Apr;7(4):281-94
17384583
Mol Carcinog. 2007 Aug;46(8):646-53
17583567
Cancer Res. 1999 Feb 15;59(4):831-42
10029072
Exp Neurol. 2009 Sep;219(1):53-7
19409385
J Biol Chem. 2001 Jul 13;276(28):26421-9
11319221
Trends Pharmacol Sci. 2006 Aug;27(8):402-9
16822554
Oncologist. 2002;7(1):17-33
11854544
Clin Cancer Res. 2002 Oct;8(10):3205-9
12374690
Proc Natl Acad Sci U S A. 1977 Sep;74(9):3805-9
20632
Cell Signal. 2009 May;21(5):745-52
19168130
Mol Endocrinol. 2003 Jan;17(1):11-26
12511603
Cell Res. 2008 Apr;18(4):436-42
18347614
J Biol Chem. 1988 May 15;263(14):6927-32
2834397
Cancer Res. 2007 Sep 15;67(18):8828-38
17875724
J Recept Signal Transduct Res. 2003;23(2-3):225-38
14626449
Mol Cell Biol. 2007 Sep;27(18):6300-8
17636030
J Biol Chem. 2007 Mar 2;282(9):6415-24
17209045
Pharmacol Rev. 1999 Dec;51(4):629-50
10581326
Biochemistry. 2007 Apr 24;46(16):4763-74
17402746
Neurochem Int. 2002 May;40(6):475-86
11850104
Steroids. 1997 Jan;62(1):21-8
9029710